SAB Deferred Long Term Liab from 2010 to 2024
| SABS Stock | USD 3.13 0.06 1.95% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 288.8 K | Current Value 274.4 K | Quarterly Volatility 4.3 M |
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 2.1 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
SAB | Deferred Long Term Liab |
Latest SAB Biotherapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of SAB Biotherapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. SAB Biotherapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
SAB Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 8,635,048 | |
| Geometric Mean | 5,222,230 | |
| Coefficient Of Variation | 49.99 | |
| Mean Deviation | 3,336,131 | |
| Median | 10,720,130 | |
| Standard Deviation | 4,316,539 | |
| Sample Variance | 18.6T | |
| Range | 10.4M | |
| R-Value | (0.69) | |
| Mean Square Error | 10.4T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (670,371) | |
| Total Sum of Squares | 260.9T |
SAB Deferred Long Term Liab History
About SAB Biotherapeutics Financial Statements
SAB Biotherapeutics shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 288.8 K | 274.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.